{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-078428","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2025-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.033710+00:00","generated_at":"2026-05-20T08:36:20.999686+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PepGen discontinues DMD program after PGN-EDO51 misses dystrophin target; shifts focus to DM1","bullets":["10 mg/kg PGN-EDO51: total dystrophin only 0.59% of normal (mean increase 0.36%); exon skipping +3.5%.","Company voluntarily discontinuing PGN-EDO51 and winding down all DMD research & development.","DM1 program prioritized; FREEDOM-DM1 15 mg/kg data expected H2 2025, FREEDOM2-DM1 5 mg/kg data Q1 2026.","PGN-EDO51 safety favorable; all treatment-related AEs mild, no serious adverse events.","Prior DM1 data (10 mg/kg single dose) showed 29% mean mis-splicing correction at safety update."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-078428","json":"https://secwatch.observer/filing/0000950170-25-078428.json","markdown":"https://secwatch.observer/filing/0000950170-25-078428.md","text":"https://secwatch.observer/filing/0000950170-25-078428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017025078428/0000950170-25-078428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017025078428/pepg-20250528.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T08:36:20.999686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}